Ribbon Acquisition Corp. (RIBB) - 10-Q Summary
Business Context and Reporting Period
Ribbon Acquisition Corp. is a Cayman Islands exempted company and a "blank check" SPAC incorporated on July 17, 2024. The company is in the process of consummating a business combination with DRC Medicine Ltd., a Japanese company specializing in AI-powered allergy and infection diagnostic kits. This filing covers the quarter and six months ended June 30, 2026. The company has until January 16, 2027, to complete its initial business combination, a deadline extended by shareholders in January 2026.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Three Months Ended June 30, 2026 |
|---|---|---|
| Net Income (Loss) | $233,154 | $(19,601) |
| Operating Expenses | $416,397 | $338,611 |
| Trust Account Income | $649,551 | $319,010 |
| Cash (Outside Trust) | $669 (as of June 30, 2026) | N/A |
| Trust Account Balance | $38,410,540 | N/A |
| Working Capital Deficit | $(1,797,571) | N/A |
| Debt (Promissory Note) | $902,938 | N/A |
Material Changes vs. Prior Period
- Redemptions: In connection with a shareholder meeting on January 9, 2026, to approve an extension of the business combination deadline, 1,436,867 public shares were redeemed for approximately $14.9 million. This significantly reduced the Trust Account balance from $51.9 million (Dec 31, 2025) to $38.4 million (June 30, 2026).
- Extension Payments: To fund the extension of the combination period to January 16, 2027, the company deposited $750,000 into the Trust Account during the six-month period (monthly payments of $125,000).
- Debt Issuance: The company issued a $600,000 promissory note to a related party (Ribbon Investment Company Ltd.) in March 2026 to fund extension payments. The balance sheet reflects a total related-party promissory note liability of $902,938.
- Profitability: The company reported a net loss for the three months ended June 30, 2026, compared to net income for the same period in 2025, primarily due to lower interest income on the reduced Trust Account balance.
Outlook, Risks, and Contingencies
- Business Combination: The company is actively pursuing a merger with DRC Medicine Ltd. The transaction involves a share exchange and the domestication of the company from the Cayman Islands to Delaware. Closing is contingent on shareholder approval, SEC effectiveness of the registration statement, and other customary conditions.
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. The company has a working capital deficit and relies on the successful completion of the business combination or additional financing from the Sponsor to meet obligations. If the combination is not completed by January 16, 2027, the company will liquidate.
- Liquidity: Cash outside the Trust Account is minimal ($669). The company relies on the Sponsor for working capital loans and extension payments. A subsequent event noted a further $125,000 deposit into the Trust Account on July 14, 2026, extending the deadline to August 15, 2026.
- Nasdaq Compliance: The company faced a delisting notice in June 2026 for failure to pay listing fees but regained compliance after paying the $75,000 past due balance.
Investor Verification Checklist
- Verify the status of the Business Combination Agreement with DRC Medicine Ltd. and any updates on closing conditions.
- Confirm the current balance of the Trust Account and the per-share redemption value following recent extension payments and redemptions.
- Review the terms of the $902,938 promissory note to the related party and the company's ability to repay it upon closing.
- Monitor the company's cash position outside the Trust Account to ensure it can meet administrative expenses and extension payments until the deadline.
- Check for any further shareholder votes required to approve the business combination or additional extensions.